MedPage Today (11/15) reports, “Affirming the ASPREE trial findings, daily aspirin failed to turn up a significant impact on dementia and cognitive function in an analysis of the ASCEND trial, but the analysis was unable to rule out a modest effect.” Researchers found that “among the some 15,000 diabetes patients in ASCEND, dementia was no less common for those randomized to aspirin or placebo, whether defined narrowly (3.3% vs 3.7%, respectively; RR 0.89, 95% CI 0.75-1.06) or broadly to also include cognitive impairment, delirium or confusion, use of dementia medications, and referral to a memory clinic or geriatric psychiatry (7.1% vs 7.8%; RR 0.91, 95% CI 0.81-1.02).” The findings were presented at the American Heart Association’s annual meeting. (SOURCE: APA Headlines)